Section of Gastroenterology and Hepatology, Department of Medicine, Baylor College of Medicine and Michael E. DeBakey Veterans Affairs Medical Center, Houston, TX, USA.
Section of Nephrology, Department of Internal Medicine, Yale University and VA Connecticut Healthcare, New Haven, CT, USA.
J Hepatol. 2023 Dec;79(6):1408-1417. doi: 10.1016/j.jhep.2023.07.010. Epub 2023 Jul 28.
BACKGROUND & AIMS: Acute kidney injury (AKI) in cirrhosis is common and associated with high morbidity, but the incidence rates of different etiologies of AKI are not well described in the US. We compared incidence rates, practice patterns, and outcomes across etiologies of AKI in cirrhosis.
We performed a retrospective cohort study of 11 hospital networks, including consecutive adult patients admitted with AKI and cirrhosis in 2019. The etiology of AKI was adjudicated based on pre-specified clinical definitions (prerenal/hypovolemic AKI, hepatorenal syndrome [HRS-AKI], acute tubular necrosis [ATN], other).
A total of 2,063 patients were included (median age 62 [IQR 54-69] years, 38.3% female, median MELD-Na score 26 [19-31]). The most common etiology was prerenal AKI (44.3%), followed by ATN (30.4%) and HRS-AKI (12.1%); 6.0% had other AKI, and 7.2% could not be classified. In our cohort, 8.1% of patients received a liver transplant and 36.5% died by 90 days. The lowest rate of death was observed in patients with prerenal AKI (22.2%; p <0.001), while death rates were higher but not significantly different from each other in those with HRS-AKI and ATN (49.0% vs. 52.7%; p = 0.42). Using prerenal AKI as a reference, the adjusted subdistribution hazard ratio (sHR) for 90-day mortality was higher for HRS-AKI (sHR 2.78; 95% CI 2.18-3.54; p <0.001) and ATN (sHR 2.83; 95% CI 2.36-3.41; p <0.001). In adjusted analysis, higher AKI stage and lack of complete response to treatment were associated with an increased risk of 90-day mortality (p <0.001 for all).
AKI is a severe complication of cirrhosis. HRS-AKI is uncommon and is associated with similar outcomes to ATN. The etiology of AKI, AKI stage/severity, and non-response to treatment were associated with mortality. Further optimization of vasoconstrictors for HRS-AKI and supportive therapies for ATN are needed.
Acute kidney injury (AKI) in cirrhosis carries high morbidity, and management is determined by the etiology of injury. However, a large and well-adjudicated multicenter database from US centers that uses updated AKI definitions is lacking. Our findings demonstrate that acute tubular necrosis and hepatorenal syndrome have similar outcomes (∼50% mortality at 90 days), though hepatorenal syndrome is uncommon (12% of all AKI cases). These findings represent practice patterns at US transplant/tertiary centers and can be used as a baseline, presenting the situation prior to the adoption of terlipressin in the US.
肝硬化合并急性肾损伤(AKI)较为常见,且发病率较高,但美国 AKI 不同病因的发病率尚不清楚。本研究旨在比较肝硬化 AKI 不同病因的发病率、实践模式和结局。
本研究为回顾性队列研究,纳入了 2019 年美国 11 个医疗网络中连续入院的 AKI 合并肝硬化的成年患者。AKI 的病因是根据预先设定的临床定义(肾前性/低血容量性 AKI、肝肾综合征相关 AKI[HRS-AKI]、急性肾小管坏死[ATN]、其他)进行判定的。
共纳入 2063 例患者(中位年龄 62 [IQR 54-69] 岁,38.3%为女性,中位 MELD-Na 评分 26 [19-31])。最常见的病因是肾前性 AKI(44.3%),其次是 ATN(30.4%)和 HRS-AKI(12.1%);6.0%的患者为其他 AKI,7.2%的患者无法分类。在本队列中,8.1%的患者接受了肝移植,36.5%的患者在 90 天内死亡。肾前性 AKI 患者的死亡率最低(22.2%;<0.001),而 HRS-AKI 和 ATN 患者的死亡率虽然较高但彼此之间无显著差异(49.0% vs. 52.7%;p=0.42)。以肾前性 AKI 为参照,90 天死亡率的校正亚分布风险比(sHR)在 HRS-AKI(sHR 2.78;95%CI 2.18-3.54;<0.001)和 ATN(sHR 2.83;95%CI 2.36-3.41;<0.001)患者中更高。在调整分析中,较高的 AKI 分期和治疗无完全反应与 90 天死亡率增加相关(均<0.001)。
AKI 是肝硬化的一种严重并发症。HRS-AKI 并不常见,其结局与 ATN 相似。AKI 的病因、AKI 分期/严重程度和治疗无反应与死亡率相关。需要进一步优化 HRS-AKI 的血管收缩剂治疗和 ATN 的支持治疗。
肝硬化合并 AKI 发病率较高,其治疗取决于病因。然而,目前缺乏来自美国中心的大型、经良好判定的多中心数据库,且该数据库使用了更新的 AKI 定义。本研究结果表明,ATN 和 HRS-AKI 的结局相似(90 天死亡率约为 50%),尽管 HRS-AKI 并不常见(占所有 AKI 病例的 12%)。这些发现代表了美国移植/三级中心的实践模式,可作为采用特利加压素治疗之前的基线情况。